Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This Phase II study is designed to study the clinical and radiologic response, as well as,
safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT)
in patients with localized high-risk or locally advanced prostate cancer who are eligible for
definitive radiation therapy (RT) and androgen deprivation therapy (ADT).